In last trading session, Leap Therapeutics Inc (NASDAQ:LPTX) saw 0.3 million shares changing hands with its beta currently measuring 0.32. Company’s recent per share price level of $0.48 trading at $0.0 or -0.52% at ring of the bell on the day assigns it a market valuation of $18.40M. That closing price of LPTX’s stock is at a discount of -897.92% from its 52-week high price of $4.79 and is indicating a premium of 2.08% from its 52-week low price of $0.47.

For Leap Therapeutics Inc (LPTX), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2.00. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.38 in the current quarter.

Leap Therapeutics Inc (NASDAQ:LPTX) trade information

Upright in the red during last session for losing -0.52%, in the last five days LPTX remained trading in the red while hitting it’s week-highest on Friday, 02/14/25 when the stock touched $0.48 price level, adding 9.33% to its value on the day. Leap Therapeutics Inc’s shares saw a change of -83.30% in year-to-date performance and have moved -5.47% in past 5-day. Leap Therapeutics Inc (NASDAQ:LPTX) showed a performance of -79.12% in past 30-days.

Wall Street analysts have assigned a consensus price target of 5.5 to the stock, which implies a rise of 91.27% to its current value. Analysts have been projecting 5.5 as a low price target for the stock while placing it at a high target of 5.5. It follows that stock’s current price would drop -1045.83% in reaching the projected high whereas dropping to the targeted low would mean a loss of -1045.83% for stock’s current value.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 28.36% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 53.39% while estimates for its earnings growth in next 5 years are of 32.44%.

On the other hand, Simplify Exchange Traded Fds-Health Care ETF and Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Sep 30, 2024 , the former fund manager was holding 1.06 shares of worth $0.51 million or 2.76% of the total outstanding shares. The later fund manager was in possession of 754.74 shares on Sep 30, 2024 , making its stake of worth around $0.36 million in the company or a holder of 1.97% of company’s stock.